Health and Healthcare

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

185 Articles

Paul Ausick | May 16, 2016 at 7:50 AM EDT

Pfizer Pays $5.2 Billion for Anacor

Pfizer has announced that it has reached a definitive agreement to acquire Anacor Pharmaceuticals in a deal valued at more…

Paul Ausick | May 12, 2016 at 4:04 PM EDT

The 52-Week Low Club for Thursday

May 12, 2016: Here are four stocks trading with relatively heavy volume among 106 equities making new 52-week lows in…

Paul Ausick | Apr 14, 2016 at 11:45 AM EDT

Valeant Debt Downgraded at S&P

Valeant Pharmaceuticals got another dose of bad news Thursday morning. Standard & Poor's Ratings Services dropped the Canadian drugmaker's corporate…

Chris Lange | Apr 10, 2016 at 10:15 AM EDT

4 Key Biopharma Movers of the Past Week

Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs.

Paul Ausick | Apr 1, 2016 at 4:04 PM EDT

The 52-Week Low Club for Friday

April 1, 2016: Here are four stocks trading with relatively heavy volume among 18 equities making new 52-week lows in…

Paul Ausick | Mar 31, 2016 at 4:04 PM EDT

The 52-Week Low Club for Thursday

March 31, 2016: Here are four stocks trading with relatively heavy volume among 13 equities making new 52-week lows in…

Jon C. Ogg | Mar 28, 2016 at 7:50 AM EDT

6 Big Companies With Completely Broken Business Models

24/7 Wall St. has identified six public companies with business models that are absolutely broken. Almost all of them are…

Trey Thoelcke | Mar 23, 2016 at 10:20 AM EDT

Why the Brussels Bombing Travel Stock Sell-Off Is Unwarranted

The fact that Tuesday's terrorist attacks at the Brussels airport brought travel stocks down is no surprise. Nevertheless, there is…

Paul Ausick | Mar 21, 2016 at 4:04 PM EDT

The 52-Week Low Club for Monday

March 21, 2016: Here are four stocks trading with relatively heavy volume among 7 equities making new 52-week lows in…

Jon C. Ogg | Mar 21, 2016 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: AK Steel, Intel, Symantec, Tesla, US Steel, Valeant and More

The top analyst upgrades, downgrades and initiations seen on Monday, March 21, include AK Steel, Intel, Symantec, Tesla, US Steel…

Chris Lange | Mar 20, 2016 at 10:40 AM EDT

How Analysts View Valeant After an Earnings Catastrophe

Releasing preliminary results may have been ill-advised to release, as the impact was absolutely catastrophic to Valeant Pharmaceuticals stock.

Chris Lange | Mar 20, 2016 at 10:10 AM EDT

5 Companies That Destroyed Shareholders Last Week

Although the markets have made their comeback, some stocks are still slowing that recovery and punishing their shareholders.

Paul Ausick | Mar 18, 2016 at 4:04 PM EDT

The 52-Week Low Club for Friday

March 18, 2016: Here are four stocks trading with heavy volume among 25 equities making new 52-week lows in Friday’s session.…

Trey Thoelcke | Mar 18, 2016 at 7:35 AM EDT

Missed the Oil Rally? Buy Caterpillar

While Caterpillar of course does not sell oil directly, it does sell the machinery that drills for it, and capital…

Paul Ausick | Mar 17, 2016 at 4:04 PM EDT

The 52-Week Low Club for Thursday

March 17, 2016: Here are four stocks trading with heavy volume among 60 equities making new 52-week lows in Thursday’s…

1 … 5 6 7 8 9 … 13

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

Pfizer Pays $5.2 Billion for Anacor

The 52-Week Low Club for Thursday

Valeant Debt Downgraded at S&P

4 Key Biopharma Movers of the Past Week

The 52-Week Low Club for Friday

The 52-Week Low Club for Thursday

6 Big Companies With Completely Broken Business Models

Why the Brussels Bombing Travel Stock Sell-Off Is Unwarranted

The 52-Week Low Club for Monday

Top Analyst Upgrades and Downgrades: AK Steel, Intel, Symantec, Tesla, US Steel, Valeant and More

How Analysts View Valeant After an Earnings Catastrophe

5 Companies That Destroyed Shareholders Last Week

The 52-Week Low Club for Friday

Missed the Oil Rally? Buy Caterpillar

The 52-Week Low Club for Thursday

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

Pfizer Pays $5.2 Billion for Anacor

The 52-Week Low Club for Thursday

Valeant Debt Downgraded at S&P

4 Key Biopharma Movers of the Past Week

The 52-Week Low Club for Friday

The 52-Week Low Club for Thursday

6 Big Companies With Completely Broken Business Models

Why the Brussels Bombing Travel Stock Sell-Off Is Unwarranted

The 52-Week Low Club for Monday

Top Analyst Upgrades and Downgrades: AK Steel, Intel, Symantec, Tesla, US Steel, Valeant and More

How Analysts View Valeant After an Earnings Catastrophe

5 Companies That Destroyed Shareholders Last Week

The 52-Week Low Club for Friday

Missed the Oil Rally? Buy Caterpillar

The 52-Week Low Club for Thursday

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not